Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

In the U.S., tigecycline has received indications for use in the treatment of complicated skin and skin structure infections (cSSSI), complicated intra-abdominal infections (cIAI), and community-acquired bacterial pneumonia (CABP) caused by susceptible strains of designated bacteria.

Tigecycline Graduates to a Black Box